What is StemEnhance Ultra?

StemEnhance Ultra concentrates and combines extracts from natures most primitive superfoods, fresh watermicroalgae and marine macroalgae, proving the body with the ultimate in stem cell support.

StemEnhance Ultra assists the bodys inherent ability for long-term self-renewal by supporting the bodys natural release ofbone marrowstem cells.

StemEnhance Ultra provides the ultimate in stem cell support. It contains a proprietary blend of highly concentrated extracts, including Fucoidan and Cerules exclusive patented ingredients StemEnhance (AFA concentrate) & Mesenkine.

StemEnhance Ultra (AFA concentrate) is shown in studies to support the release of stem cells from the bone marrow.

Fucoidan (undaria pinnatifida) is a marinealgaewell known to support the immune system. Cerules fucoidan comes from undaria harvested from pristine environments like the Tasman Sea and Patagonia. Fucoidan from Undaria Pinnatifida has been documented to increase the number of circulatingstem cells.

Mesenkine is a unique extract from Spirulina, isolated through Cerules patented extraction process, that supports the release and homing of stem cells by balancing key messengers involved in stem cell function.

StemEnhance Ultra does not contain dairy, wheat, gluten, peanut, soy, corn, or allergens. There are no artificial flavors or colors. It is 100% vegetarian, non-GMO, and free from herbicides and pesticides.

The primary roles of adult stem cells in a living organism are to maintain and repair the tissue in which they are found. Stem cells released from the bone marrow can migrate to various tissues where they contribute to the process of tissue repair.

Suggested usage is 2 capsules 1 to 2 times daily.

The clinical studies were done using adults therefore we recommend StemEnhance Ultra for adult consumption, however there are no known contraindications for children.

StemEnhance Ultra is formulated for human consumption. We know of no reason that it may be harmful to pets. AFA and spirulina have been used in the pet nutrition industry for years. However, no studies have been done using the product for pet consumption. Please consult with your Veterinarian.

StemEnhance Ultra is the result of 16 years of research and constitutes the most efficacious and scientifically provenstem cell nutritionproduct on the market.

Through multiple clinical trials, StemEnhance Ultra was documented to optimize stem cell function in the body by increasing the number of bothstem cellsand and Endothelial Progenitor Cells (EPCs) in the bloodstream, supporting optimum renewal and repair of tissues and organs.

StemEnhance Ultra also contains Mesenkine, that was shown to increase the blood concentration of G-CSF that plays a key role in stem cell release.

See StemEnhance research here.

As stated on the label, the vegetarian capsule is made from hypromellose. Hypromellose is cellulose derivative or plant fiber.

StemEnhance Ultra ingredients are certified Kosher.It is not certified Halal.

There is an expiration date at the bottom of each bottle. StemEnhance Ultra has a shelf life of 3 years from date of manufacture. All bottles should be stored in a cool, dry place.

Yes! The Cerule products can be consumed together and were designed to enhance the beneficial effects of each other. We know of no concerning interaction between the Cerule products and other nutritional supplements.

Like many green foods, StemEnhance Ultra contains naturally occurring vitamin K, which could interfere with vitamin K blockers used to thin the blood, such as coumadin.

If you have any health condition and/or are using medication, then consult your attending health care provider before consuming any nutritional supplement.

For some people, due to their conditions and medications, they need to manage their intake of certain nutrients. Below are the amounts of naturally occurring nutrients found in the plant based ingredients within StemEnhance Ultra:

Vitamin K: around 20 ug per serving (2 capsules)Iron: 0.34 mg per serving (2 capsules)Iodine: around 4 ug per serving (2 capsules)Sodium: 9.66 mg per serving (2 capsules)PEA: >0.5%

Pregnancy and nursing are considered special conditions. We recommend that your attending Doctor(s) be made aware of any and all supplements consumed during this time. At this time, we do not advise StemEnhance Ultra consumption during pregnancy.

Go here to read the rest:
StemEnhance Ultra: The Best Stem Cell Supplement - Our ...

Active Comparator: Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd

Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.

Bortezomib 1.3 mg/m^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Other Name: Velcade

Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Other Name: Revlimid

Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.

Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.

Bortezomib 1.3 mg/m^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Other Name: Velcade

Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Other Name: Revlimid

Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

View original post here:A Study Comparing Daratumumab, VELCADE (Bortezomib ...

See the article here:
Pet Stem Cell Therapy

To our knowledge, The Institute is the first of its kind in the United States and it will primarily be housed here at Saint Francis Pet Care Center. Patients will experience the kind and thorough care that many of you have already come to know. Donations and grants received by our non-profit 501c3 Vets for Pets will be utilized to promote awareness and educate pet parents about Stem Cell Therapy. We will continue to collaborate with both veterinary and human researchers to assist with FDA approval and development of the most effective treatment protocols.

As I pour over the research, the possibilities of treatment are almost limitless. At this point, our treatment will be relegated to dogs, but we anticipate the ability to treat other species soon. Please click here to see what current and upcoming studies we are conducting. For patients who do not qualify for a study, we will have the ability to still employ stem cell therapy on an individual basis. If you would like to learn more about stem cell therapy in pets, please click the link to view Stem Cells 101.

For further inquiry, please feel free to contact us.

See the original post here:
About Us - The Pet Stem Cell Institute

Background

Pre-transplantation 18F-fluorodeoxyglucose (FDG) PET-negativity is one of the strongest predictors of outcome after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) for patients with relapsed or refractory Hodgkin's lymphoma. In this study, we assessed the feasibility and activity of PET-adapted salvage therapy with brentuximab vedotin, followed by augmented ifosfamide, carboplatin, and etoposide (ICE).

In this non-randomised, open-label, single-centre, phase 2 trial, we enrolled patients with relapsed or refractory Hodgkin's lymphoma who had failed one previous doxorubicin-containing chemotherapy regimen. All patients received weekly infusions of 12 mg/kg brentuximab vedotin on days 1, 8, and 15 for two 28 day cycles. After completion of brentuximab vedotin treatment, patients received a PET scan. Patients who achieved PET-negative status (a Deauville score of 1 or 2) proceeded directly to HDT/ASCT; those with persistent abnormalities on PET received two cycles of augmented ICE (augICE; two doses of ifosfamide 5000 mg/m2 in combination with mesna 5000 mg/m2 continuous infusion over 24 h, days 1 and 2; one dose of carboplatin AUC 5, day 3; three doses of etoposide 200 mg/m2 every 12 h, day 1) before consideration for HDT/ASCT. Only patients with persistent abnormalities on PET after brentuximab vedotin received augICE; however, all patients in the intention-to-treat population were assessed for the primary outcome, which was the proportion of patients who were PET-negative after brentuximab vedotin alone or brentuximab vedotin followed by augICE. This study is registered with ClinicalTrials.gov, number NCT01508312, and is no longer accruing patients.

Between Jan 5, 2012, and Oct 4, 2013, we enrolled 46 patients. One patient was deemed ineligible, and not evaluable, before treatment initiation owing to having nodular, lymphocyte-predominant Hodgkin's lymphoma and thus 45 patients received treatment. After brentuximab vedotin, 12 patients (27%, 95% CI 1340) were PET-negative and proceeded to HDT/ASCT. 33 (73%, 95% CI 6086) patients were PET-positive after brentuximab vedotin; one PET-positive patient withdrew consent, therefore 32 PET-positive patients received augICE, 22 (69%, 95% CI 5385) of whom were PET-negative. Overall, 34 patients (76%, 95% CI 6289) achieved PET-negativity. All 44 patients who completed treatment as per protocol proceeded to receive HDT/ASCT. Brentuximab vedotin was well tolerated and associated with few grade 34 adverse events including hyperglycaemia (two [4%] patients, grade 3), nausea (one [2%], grade 3), hypoglycaemia (one [2%], grade 3 and one [2%], grade 4), and hypocalcaemia (one [2%], grade 3 and one [2%], grade 4).

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augICE resulted in a high proportion of patients with relapsed or refractory Hodgkin's lymphoma achieving PET-negativity, and therefore could optimise the chance of cure after HDT/ASCT.

See more here:
PET-adapted sequential salvage therapy with brentuximab ...

Veterinary healthcare from your pets point of view

Clickbelow towatch our 2-minute video where Dr. Chris Lee explains our unique philosophy:

Pet Universe Vet Adelaide is a family-run veterinary clinic that has been operating for over 10 years in Adelaides northern suburbs. We offer a range of services to improve your pets health and wellness including:

Our vet centre is friendly, caring and professional, helping to ease your pets fears and your own. On top of excellent veterinary care, we also provide relaxing background music, gentle handling, an optimum pain-relief policy and lots of treats & fuss!

Pets can fall sick at any time. So to offer quality care, our Broadview veterinary clinic is now available for appointments 7 days a week. You can book with me or any of my associates at Broadview or at our Northgate vet practice (open 6 days a week). Contact us at Pet Universe when you need a trusted vet Adelaide.

The rest is here:
Vet Adelaide | Quality Veterinary Healthcare | Pet Universe

At Cell Therapy Sciences we harness the regenerative properties of mesenchymal stem cells to prepare clinical therapies for dogs and horses. Based on our own research, we have optimised these therapies to ensure you receive the very best cells for your patients.

From a small piece of an animal's own tissue, many millions of regenerative cells can be grown by culture-expansion in our specialised VMD-authorised laboratory. We have developed our own, evidence-based procedures for harvest, implantation and transportation, which are simple and practical for vets - and ensure the highest possible standards of safety and quality for pets.

The Evidence Base?

Culture-expanded, mesenchymal stem cells (MSCs) have been used to treat lameness, pain and degenerative joint problems in dogs and horses for more than 10 years. The most recent clinical evidence includes a number of significant, well controlled and large clinical investigations into canine OA (e.g. Shah et al 2018; Harman et al 2016) with authors reporting that MSCs can not only reduce pain and inflammation, but also improve quality of life and enhance tissue repair. The World Small Animal Veterinary Association recognises stem cells in their pain management protocol and include stem cell injectionsfor DJD in dogs and cats in their Pain Council Guidelines.

Why use our culture-expanded stem cells?

We are the most experienced companion animal stem cell laboratory in the UK, having prepared > 2,000 stem cell treatments for intra-articular and intravenous use in client-owned dogs and cats.

We conduct our own laboratory research and have ongoing scientific collaborations with leading stem cell centres, including University College London, Stem Cells Scotland and Coventry University.

Four clinical investigations to date in moderate to severe canine OA have reported significant reductions in pain and improvements in functional mobility following intra-articular injections using our stem cell preparations. These include the first reported study to use two validated arthritis questionnaires to evaluate clinical outcomes in OA (Armitage et al 2018).

Our VMD-authorised cryogenic storage and transport system maximises stem cell quality and viability at point of care and has been shown to be superior to shipping at ambient temperatures.

See the original post here:
Cell Therapy Sciences

Active Comparator: Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd

Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.

Bortezomib 1.3 mg/m^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Other Name: Velcade

Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Other Name: Revlimid

Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.

Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.

Bortezomib 1.3 mg/m^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Other Name: Velcade

Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Other Name: Revlimid

Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

View original post here:
A Study Comparing Daratumumab, VELCADE (Bortezomib ...

In December 1988 Sarah Smith was in a serious car accident. Sarah became paralyzed from the waist down. She seldom felt nerves in her legs and feet when touched or tested and she could not walk or stand. The muscles in her hands had atrophied, making it impossible for her to open them. Sarahss health gradually got worse due to lack of exercise and movement. In essence she lived in a motorized wheel chair. After reading an article Sarah contacted the Rehabilitation Institute of Detroit, Michigan. Following grueling tests and therapy Sarah flew to Beijing, China and received Olfactory Ensheathing cell surgery. They implanted stem cells above and below the injured portion of her spine. Immediately she could feel a reaction. Her legs were tingling with sensation. Her right hand opened and closed. Today she is in a manual wheel chair and can kick both legs. With adequate knowledge of stem cell research, learning the benefits acquired through stem cell therapy, and recognizing that support for stem cells is on the rise; it is apparent that even though people believe it is against the laws of God, the positive medical benefits resulting from stem cell research out weigh the negative social penalties.

Due to confusion and general lack of knowledge stem cell research is sometimes wrongly thought of as unethical. Stem cells are model cells found all through the body that have the ability to possess concentrated roles. These cells are grown to imitate blood, bone, brain, or skin cells among others (Heled, 2008). There are different kinds of stem cells deriving from different areas that produce different results. Embryonic or fetal stem cells are believed to be the most influential and controversial in stem cell research. According to the American Journal of Health Education, (embryonic stem cells) can differentiate into almost any type of cell that makes up the body (2008). They originate from four different places: existing stem cell lines, aborted or miscarried fetuses, discarded embryos from fertilization, or cloned embryos. Adult stem cells are harder to manipulate; however, they do offer great insight into stem cell research. Adult stem cells can be found in different parts of the brain and bone marrow (Eve, Marty, McDermott, Klasko, Sanberg, 2008). Because of federal funding there is more adaptability with adult stem cells making them more available. Placental or umbilical cord blood stem cells contain a smaller level of stem cells, but have resulted to be beneficial in the treatment of different disorders. Current research of these cells has brought about encouraging possibilities, but as with all new ideas it does need to be explored more. Stem cell research and the cloning of humans and animals is not the same thing. The cloning of humans to full term is banned more or less across the globe. In some cases short term cloning was performed to allow for the creation and mining of stem cells; however, following the tests the cloned embryos were terminated (Eve, Marty, McDermott, Klasko, Sanberg, 2008). World wide a handful of animals have been cloned, but were inundated with problems resulting in tighter restrictions on human stem cell research. Recent research on cloned animals implies that the duplicated cells do not restart their lifespan, insuring an earlier death. Stem cells are thought to be the foremost uncultivated source for deterrence and healing of many diseases (see Chart 1). The process has shown new hope for many horrible degenerative diseases. Mice reproduced to show signs of Sandhoff disease, an adolescent disorder, implanted with stem cells revealed progress. Depleted levels of the Hexosaminidase trigger the disease. It was found that by implanting the stem cells it replenished the low levels rebuilding the dwindling amount. Additionally, with the help of stem cells scientists are initiating modern methods to regenerate brain cells used to treat Parkinsons disease. By replacing defective cells with...

References: China Post. (2007). Researchers join stem cell experiment on spinal injuries. July 8, 2008, from http://www.chinapost.comDevitt, T. (2007). Human Embryonic Research is Necessary. Detroit, MI: Greenhaven PressEve, D., Marty, D., McDermott, R., Klasko, S., & Sanberg, P. (2008, May-June). Stem Cell Research and Health EducationHaugen D., & Musser, S. (2007). Introduction to human embryo experimentation: At issueHeled, Yaniv. (2008, Wntr). On presidents, agencies, and the stem cells between them: a legal analysis of Preseident Bushs and the federal governments policy on the funding of research involving human embryonic stem cellsLindsay, R. (2008). Embryonic stem cell research is ethical. Detroit, MI: Greenhaven PressWalker, P. (2006, November 20). Stem cell cure for diabetes. Chemistry and Industry,11(1), 22Weiss, R. (2004, June 10). Stem cells an unlikely therapy for alzheimer 's. Washington Post, p

Please join StudyMode to read the full document

Link:
Stem Cell Therapy Essay - 2136 Words

Helping Pets Heal Themselves!

Adult Stem Cell Therapy is a new innovative treatment option for dogs suffering from osteoarthritis, hip dysplasia or other joint related issues. Patients can be treated on an outpatient basis with their own stem cells collected, processed and administered the same day. Not only does stem cell therapy reduce pain and inflammation but it also restores quality of life and range of motion and regenerates tendons, ligaments and joint tissue.

Utilizing Adult Stem Cells is the wave of the future, says Zoran Djordjevich, DVM of Mohnacky Animal Hospital of Carlsbad, who has successfully treated numerous patients with great results. Owners are reporting their pets have made tremendous improvement and are enjoying a more active lifestyle. Dr George is currently using stem cells to enhance his advanced Canine Total Hip Replacement implant surgery as well, promoting faster healing in these patients. To find out more on how stem cell therapy can help your pet call us today!

Stem cell therapy is a procedure that harnesses the bodys innate regenerative and healing processes to treat diseases. The procedure at Mohnacky Animal Hospital uses adult stem cells isolated from your pets fat tissue, a rich source of stem cells. Studies have shown that these stem cells can develop into many different types of cells and tissues, including cartilage and bone. They also secrete many biological factors that promote healing. In a stem cell procedure, cells are isolated from a small amount of fat and then injected at the site of injury or disease. Cells are often given intravenously as well since stem cells have the ability to home to sites of injury and inflammation. In the treatment of osteoarthritis in joints, for example, stem cells can generate new cartilage and bone plus secrete potent anti-inflammatory factors, thereby replacing lost or damaged tissues, reducing pain, and increasing mobility.

Stem cell therapy uses the bodys own regenerative cells and the myriad of proteins (cytokines, growth factors) they produce to help the patient heal itself naturally. Stem cells treat the source of the problem by repairing damaged tissue and/or halting the disease process. Other medical treatments, such as anti-inflammatory drugs, generally address just the symptoms. With the advanced protocol used at Mohnacky Animal Hospital, over 95% of animals treated for osteoarthritis show significant improvement.

Stem cell therapy is considered quite safe. It uses the animals own stem cells so there is no risk of rejection. Minor surgery under anesthesia is required to collect the fat tissue. On a dog, this surgery is simpler than a spay, and is completed in about 20 minutes.

More here:
Pet Stem Cell Therapy | Mohnacky Animal Hospitals in ...

What happens to my pet when they come in for stem cell therapy?

First, your vet will put your pet under general anesthesia. Then, she will make a small incision and collect 2-4 tablespoons of fat (either in the belly or behind the shoulder blades). MediVet provides on-site training this process ensures your pets cells are isolated and activated in the proper manner.

The surgical time requiring anesthesia is typically less than 30 minutes. The cells are isolated, activated and re-administered on site so your pet can go home that same day.

We recommend that the patient be limited to activity within the first 10 days. It is likely your pet will be feeling good and want to exert themselves, however we recommend limiting physical activity so the cells have the ability to work in repairing injuries. Improvements are typically seen within the first two weeks and continue to improve over the next few months. Veterinarians report responses from initial treatments lasting 18-24 months.

Rehabilitation Schedule

MediVets patented stem cell procedure allows us to isolate stem cells from your pets own fat tissue, activate them and reintroduce them directly into the damaged areas all in one visit. The goal of this revolutionary procedure is to provide a potent anti-inflammatory effect promoting cartilage and other tissue regeneration ultimately creating a healthier environment for the affected area. Most importantly, its an all-natural approach to healing without the adverse side effects. One example, in the case of arthritis, stem cells can become new cartilage cells, thus reducing pain and increasing mobility.

We typically see about 18-24 months of relief after the initial treatment and even longer when treatment is sought at earlier stages. Most pet owners choose to bank cells, so re-treatment is easy and cost effective. MediVet has banking facilities in Kentucky, Australia and Europe. If symptoms return, your vet merely requests a dose of cells from the bank, and injects them. No surgery is necessary.

Stem cell therapy for animals has been commercially available since 2004. MediVet pioneered in-clinic treatment options around 2010 and has now successfully treated thousands of animals globally.

Stem cells treat the source of the problem by becoming new tissue replacing damaged tissue. Other treatments, such as NSAIDs, merely attempt to reduce symptoms. The treatment is very low risk, because it uses the animals own stem cells. With MediVets technology in a recent study conducted by four independent Veterinarians over 95% of animals treated show improvement. For pet owners, there are two main advantages to MediVet.155 Canine Study

Our typical patient has osteoarthritis (hip dysplasia, degenerative joint disease, calcifications, common degeneration and inflammation), soft tissue injuries (cruciate injuries, tears, ruptures, inflammation) or needs accelerated healing of fractures. We know a lot about these conditions, and over 95% of these patients get better, with MediVets Stem Cell Therapy. We also treat other cases under compassionate use. We know less about these conditions, but are seeing some exciting results. Some of those conditions are: degenerative myelopathy, feline gingivitis, end-stage renal disease, liver and kidney failure, allergy, auto-immune, inflammatory bowel disease, pulmonary fibrosis, IMHA, atopy, and spine trauma. Our veterinarians would love to talk with you if you have questions about any of these conditions or would like to submit your pet for a compassionate use trial.

Yes, this procedure is very safe. The biggest risk as in any surgical procedure is using anesthetic, to remove the fat tissue. On a typical dog, veterinarians report this procedure is easier than a spay. The fat is collected in about 20 minutes. Processing the sample is done carefully by one of our highly trained veterinary technicians (fully trained by MediVet). In the thousands of animals treated by MediVet, they have not observed any significant negative side-effects from stem cell therapy.

Follow this link:
Stem Cell Therapy - FloridaWild Vet Hospital